Table 2 Variable notations, definitions, and dimensions.
From: Age-Structured Population Modeling of HPV-related Cervical Cancer in Texas and US
Variable | Definition | Dimensions i=23 age groups l=3 sexual activity groups c=2 gender groups |
|---|---|---|
X | Susceptible, female persons | l, i, c+1 |
V1 | Vaccinated with 1 dose | l, i, c+1 |
V2 | Vaccinated with 2 doses | l, i, c+1 |
VS | Vaccinated with waned immunity | l, i, c+1 |
Y | Infected persons | l, i, c+1 |
UF | Persistently infected, only female | l, i, c |
ZS | Recovered without sero-conversion | l, i, c+1 |
Z | Recovered with sero-conversion | l, i, c+1 |
WS | Infected vaccinated with waned immunity | l, i, c+1 |
W1 | Infected vaccinated with 1 dose | l, i, c+1 |
W2 | Infected vaccinated with 2 doses | l, i, c+1 |
PSF | Persistently infected vaccinated, only female | l, i, c |
P1F | Persistently infected vaccinated with 1 dose, only female | l, i, c |
P2F | Persistently infected vaccinated with 2 doses, only female | l, i, c |
QS | Recovered vaccinated without sero-convertion | l, i, c+1 |
Q | Recovered vaccinated with sero-convertion | l, i, c+1 |
Hx | Population of females with hysterectomy | l, i, c |
Hy | Population of females with hysterectomy that are infected | l, i, c |
Hz | Population of females with hysterectomy that were infected, recovered, seroconverted | l, i, c |
Hzs | Population of females with hysterectomy that were infected, recovered, not seroconverted | l, i, c |
Hv1 | Vaccinated with 1 dose, persons with hysterectomy | l, i, c |
Hv2 | Vaccinated with 2 doses, persons with hysterectomy | l, i, c |
Hvs | Vaccinated with waned immunity, persons with hysterectomy | l, i, c |
Hw | Infected vaccinated, persons with hysterectomy | l, i, c |
Hqs | Recovered vaccinated without sero-convertion, persons with hysterectomy | l, i, c |
Hq | Recovered vaccinated with sero-convertion, persons with hysterectomy | l, i, c |
N | Total number of persons | l, i, c |
CIN2 | Undetected cervical intraepithelial neoplasia 2 | l, i, c |
CIN3 | Undetected cervical intraepithelial neoplasia 3 | l, i, c |
CIS | Undetected carcinoma in situ 1 | l, i, c |
DCIN2 | Detected cervical intraepithelial neoplasia 2 | l, i, c |
DCIN3 | Detected cervical intraepithelial neoplasia 3 | l, i, c |
DCIS | Detected carcinoma in situ 1 | l, i, c |
TCIN2 | Treated cervical intraepithelial neoplasia 2 | l, i, c |
TCIN3 | Treated cervical intraepithelial neoplasia 3 | l, i, c |
TCIS | Treated carcinoma in situ | l, i, c |
ICIN2 | Infectious after treatment cervical intraepithelial neoplasia 2 | l, i, c |
ICIN3 | Infectious after treatment cervical intraepithelial neoplasia 3 | l, i, c |
ICIS | Infectious after treatment carcinoma in situ 1 | l, i, c |
CCl | Undetected local cervical cancer | l, i, c |
CCr | Undetected regional cervical cancer | l, i, c |
CCd | Undetected distant cervical cancer | l, i, c |
DCCl | Detected local cervical cancer | l, i |
DCCr | Detected regional cervical cancer | l, i |
DCCd | Detected distant cervical cancer | l, i |
SCC | Cervical cancer survivals | l, i |
